Pain Relief with JAK Inhibitors or Anti-TNFs ?

Save

Targeted drugs for rheumatoid arthritis (RA) are not created equal when it comes to pain relief, a retrospective study from Sweden indicated, although the differences appeared to be modest.

INVIGORATE-2 Study - IV Secukinumab in Active Psoriatic Arthritis

Save

The INVIGORATE-2 trial reports that intravenous secukinumab is both effective and safe in patients with active psoriatic arthritis, demonstrating improvements on par with subcutaneous secukinumab.

Bimekizumab FDA Approved for Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis

Save

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved bimekizumab-bkzx (Bimzelx) for the treatment of 3 chronic inflammatory disorders.

Mycophenolate in New-Onset SLE

Save

How aggressively do you treat newly diagnosed new-onset systemic lupus erythematosus (SLE), or should you wait for organ involvement?

TREAT EARLIER - Methotrexate in Clinically Suspect Arthralgia Patients

Save

Lancet Rheumatology has published the results of the TREAT EARLIER trial, showing the prevention of rheumatoid arthritis may be enhanced by risk stratification, particularly in anti-citrullinated protein antibody (ACPA)-negative people with clinically suspect arthralgia.

Antidepressants for Pain are Weakly Effective

Save

University of Sydney research has found people over 65 are being prescribed antidepressants as pain treatment based on international guidelines that use limited evidence. The study found that in the last 40 years there have been only 15 trials globally focusing on the benefit of antidepressants for pain in older people. This study fills a much-needed gap in research by bringing together the information from these trials to look at the efficacy and harms of antidepressants for acute and chronic non-cancer pain in those over 65 years old.

FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis

Save

Increased Cardiovascular Events in Lupus

Save

A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.

BSR Guidelines for Systemic Sclerosis Management

Save

The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion. 

Different Autoantibody Phenotypes in Juvenile and Adult Myositis

Save

A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.